Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Lancet Psychiatry. 2020 Jul 28;7(10):865–874. doi: 10.1016/S2215-0366(20)30290-X

Table 1.

Characteristics of all participants included in both interim and final analysis stages of the trial. Data show frequencies, percentages, means and 95% Interval Estimates for the placebo (n=23), 200mg CBD (n=12), 400mg CBD (n=24) and 800mg CBD (n=23) groups

Placebo 200mg CBD 400mg CBD 800mg CBD
Age 24.87
(18.55, 43.35)		 27.33
(19.28, 39.08)		 26.58
(19.15, 41.25)		 27.43
(19.00, 36.90)
Sex (%male, male/female) 73.91%, 17/6 75.00%, 9/3 70.83%, 17/7 69.57%, 16/7
DSM-5 CUD symptoms at screening assessment 8.61
(7.63, 9.58)		 8.67
(7.63, 9.70)		 9.00
(8.29, 9.71)		 8.48
(7.39, 9.57)